Patents by Inventor Ulrich Kohnert
Ulrich Kohnert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10047162Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.Type: GrantFiled: August 21, 2015Date of Patent: August 14, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Hubert Kettenberger, Stefan Klostermann, Ulrich Kohnert, Sebastian Neumann
-
Publication number: 20160068602Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.Type: ApplicationFiled: August 21, 2015Publication date: March 10, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: HUBERT KETTENBERGER, STEFAN KLOSTERMANN, ULRICH KOHNERT, SEBASTIAN NEUMANN
-
Patent number: 9187550Abstract: A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence.Type: GrantFiled: August 25, 2011Date of Patent: November 17, 2015Assignee: Hoffman—La Roche Inc.Inventors: Martin Bader, Monika Baehner, Juergen Fingerle, Ulrich Kohnert, Jean-Luc Mary, Silke Mohl
-
Patent number: 9150641Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.Type: GrantFiled: December 17, 2010Date of Patent: October 6, 2015Assignee: Hoffmann—La Roche Inc.Inventors: Hubert Kettenberger, Stefan Klostermann, Ulrich Kohnert, Sebastian Neumann
-
Publication number: 20150080303Abstract: The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.Type: ApplicationFiled: September 27, 2013Publication date: March 19, 2015Inventors: Ulrich Kohnert, Sylke Pohling, Klaus Hellerbrand, Peter Happersberger
-
Patent number: 8546334Abstract: The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.Type: GrantFiled: March 27, 2002Date of Patent: October 1, 2013Assignee: Scil Technology GmbHInventors: Ulrich Kohnert, Sylke Pohling, Klaus Hellerbrand, Peter Happersberger
-
Publication number: 20130065277Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.Type: ApplicationFiled: December 17, 2010Publication date: March 14, 2013Inventors: Hubert Kettenberger, Stefan Klostermann, Ulrich Kohnert, Sebastian Neumann
-
Patent number: 8257728Abstract: The present invention relates to a method for producing a device comprising the steps of (a) providing a solution comprising dissolved osteoinductive protein, (b) contacting the solution of the preceding step with a carrier containing a surface of metal or a metal alloy, (c) allowing coating of the surface of said carrier with said dissolved protein and (d) drying of the coated carrier obtained in step (c) wherein steps (b) to (d) are carried out under a reduced concentration of oxygen. The invention also encompasses a device obtainable by the method of the present invention. Moreover, the present invention relates to a pharmaceutical composition comprising the said device and to the use of the device for the preparation of a pharmaceutical composition to be used for an accelerated osseointegration and new bone formation. Finally, the present invention relates to a kit comprising the device of the present invention.Type: GrantFiled: May 28, 2010Date of Patent: September 4, 2012Assignee: Scil Technology GmbHInventors: Klaus Hellerbrand, Nicola Beaucamp, Ulrich Kohnert
-
Publication number: 20120190610Abstract: A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence.Type: ApplicationFiled: August 25, 2011Publication date: July 26, 2012Inventors: Martin Bader, Monika Baehner, Juergen Fingerle, Ulrich Kohnert, Jean-Luc Mary, Silke Mohl
-
Publication number: 20110020658Abstract: The present invention relates to a method for producing a device comprising the steps of (a) providing a solution comprising dissolved osteoinductive protein, (b) contacting the solution of the preceding step with a carrier containing a surface of metal or a metal alloy, (c) allowing coating of the surface of said carrier with said dissolved protein and (d) drying of the coated carrier obtained in step (c) wherein steps (b) to (d) are carried out under a reduced concentration of oxygen. The invention also encompasses a device obtainable by the method of the present invention. Moreover, the present invention relates to a pharmaceutical composition comprising the said device and to the use of the device for the preparation of a pharmaceutical composition to be used for an accelerated osseointegration and new bone formation. Finally, the present invention relates to a kit comprising the device of the present invention.Type: ApplicationFiled: May 28, 2010Publication date: January 27, 2011Applicant: SCIL TECHNOLOGY GMBHInventors: Klaus Hellerbrand, Nicola Beaucamp, Ulrich Kohnert
-
Patent number: 7763270Abstract: The present invention relates to a method for producing a device comprising the steps of (a) providing a solution comprising dissolved osteoinductive protein, (b) contacting the solution of the preceding step with a carrier containing a surface of metal or a metal alloy, (c) allowing coating of the surface of said carrier with said dissolved protein and (d) drying of the coated carrier obtained in step (c) wherein steps (b) to (d) are carried out under a reduced concentration of oxygen. The invention also encompasses a device obtainable by the method of the present invention. Moreover, the present invention relates to a pharmaceutical composition comprising the said device and to the use of the device for the preparation of a pharmaceutical composition to be used for an accelerated osseointegration and new bone formation. Finally, the present invention relates to a kit comprising the device of the present invention.Type: GrantFiled: July 9, 2003Date of Patent: July 27, 2010Assignee: Scil Technology GmbHInventors: Klaus Hellerbrand, Nicola Beaucamp, Ulrich Kohnert
-
Publication number: 20060240062Abstract: The present invention relates to a method for producing a device comprising the steps of (a) providing a solution comprising dissolved osteoinductive protein, (b) contacting the solution of the preceding step with a carrier containing a surface of metal or a metal alloy, (c) allowing coating of the surface of said carrier with said dissolved protein and (d) drying of the coated carrier obtained in step (c) wherein steps (b) to (d) are carried out under a reduced concentration of oxygen. The invention also encompasses a device obtainable by the method of the present invention. Moreover, the present invention relates to a pharmaceutical composition comprising the said device and to the use of the device for the preparation of a pharmaceutical composition to be used for an accelerated osseointegration and new bone formation. Finally, the present invention relates to a kit comprising the device of the present invention.Type: ApplicationFiled: July 9, 2003Publication date: October 26, 2006Inventors: Klaus Hellerbrand, Nicola Beaucamp, Ulrich Kohnert
-
Publication number: 20060088565Abstract: The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein said carrier is homogenously coated with said protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of said device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.Type: ApplicationFiled: March 27, 2002Publication date: April 27, 2006Inventors: Ulrich Kohnert, Sylke Pohling, Klaus Hellerbrand, Peter Happersberger
-
Patent number: 6025142Abstract: The invention relates to an antibody which inhibits the binding between u-PA and u-PAR to an extent of at least 90% in an assay as defined in the specification, or an active fragment or immunological equivalent of said antibody. Examples of such antibodies are deposited Jul. 7, 1994 at Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSM) with accession numbers DSM ACC2178 and DSM ACC2179 under the terms and conditions of the Budapest Treaty. The invention furthermore relates to a method for detecting or quantifying u-PAR or a glycosylation variant of u-PAR in a sample by use of an antibody according to the invention.Furthermore, the invention relates to a method for the manufacture of a therapeutic agent for preventing or counteracting localized proteolytic activity using of an antibody of the invention as well as to use of an antibody according to the invention for the preparation of a diagnostic agent which is capable of targeting a diagnostic to a cell that contains a u-PAR on the surface.Type: GrantFiled: June 2, 1995Date of Patent: February 15, 2000Assignees: Boehringer Mannheim GmbH, Cancerforskningsfonden af 1989Inventors: Ulrich Pessara, Ulrich Weidle, Bernhard Konig, Ulrich Kohnert, Ilse Bartke, Keld Dan.o slashed., Michael Ploug, Vincent Ellis
-
Patent number: 5973118Abstract: A polypeptide which has the activity of an inhibitor DE-3 from Erythrina caffra and which reversibly and selectively binds serine proteases from a protein mixture is obtainable by culturing prokaryotic or eukaryotic host cells which have been transformed or transfected with a nucleic acid that codes for the said polypeptide in a manner that allows the host cells to express the said polypeptide under suitable nutrient conditions and isolating the said polypeptide, wherein the polypeptide has an amino acid sequence which is functionally analogous to SEQ ID NO:2, has a partial region that is more than 85% homologous to the region of amino acids 39-139 of this sequence, has two disulfide bridges and begins N-terminally with SEQ ID NO:4 or with a SEQ ID NO:4 extended N-terminally by methionine and has a binding capacity for tissue plasminogen activators of 1.25 MU/ml and more and is particularly suitable for purifying plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).Type: GrantFiled: October 3, 1997Date of Patent: October 26, 1999Assignee: Roche Diagnostics GmbHInventors: Ulrich Kohnert, Anne Stern, Manfred Wozny, Stephan Fischer
-
Patent number: 5958722Abstract: Process for purifying serine proteases from a protein mixture by binding the serine protease to an immobilized polypeptide with the activity of an inhibitor DE-3 from Erythrina caffra, removing unbound components from the protein mixture, detaching the serine protease from the inhibitor and separating the immobilized inhibitor from the soluble serine protease and isolating serine protease which is characterized in that a polypeptide is used as the polypeptide which is the product of a prokaryotic or eukaryotic expression of an exogenous nucleic acid. This inhibitor is distinguished by an improved specific activity and is particularly suitable for the purification of plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).Type: GrantFiled: September 13, 1996Date of Patent: September 28, 1999Assignee: Boehringer Mannheim GmbHInventors: Ulrich Kohnert, Anne Stern, Stephan Fischer
-
Patent number: 5908625Abstract: The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.Type: GrantFiled: January 20, 1998Date of Patent: June 1, 1999Assignee: Boehringer Mannheim GmbHInventors: Ulrich Kohnert, Anne Stern, Ulrich Martin, Stephan Fischer
-
Patent number: 5747030Abstract: The invention relates to pharmaceutical preparations containing plasminogen activators, sugars and tranexamic acid, in the form of a lyophilisate or an injection or infusion solution. In particular, the preparations contain a sugar, phosphate buffer, tranexamic acid as well as a surfactant and the liquid solutions preferably have a pH value of 5.5-6.5.Type: GrantFiled: August 21, 1996Date of Patent: May 5, 1998Assignee: Boehringer Mannheim GmbHInventors: Ulrich Kohnert, Stephan Fischer, Hans-Jorg Markl, Heinrich Woog
-
Patent number: 5723122Abstract: The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while. demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.Type: GrantFiled: June 1, 1995Date of Patent: March 3, 1998Assignee: Boehringer Mannheim GmbHInventors: Ulrich Kohnert, Anne Stern, Ulrich Martin, Stephan Fischer
-
Patent number: 5409699Abstract: The invention is a pharmaceutical composition containing a glycosylated protein having human tissue type plasminogen activator activity of at least 1.4 MU/ml, citrate, and at least one of a number of various compounds. The composition has a pH ranging from 4.5 to 9.Type: GrantFiled: July 19, 1991Date of Patent: April 25, 1995Assignee: Boehringer Mannheim GmbHInventors: Ulrich Kohnert, Rainer Rudolph